

MARKET REPORT



Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsight's "Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Chronic Heart Failure epidemiology and market outlook for the 7MM.

Markets Covered

- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan

Study Period: 2016-2027

Chronic Heart Failure Understanding and Treatment Algorithm

The market report provides the overview of the Chronic Heart Failure by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Chronic Heart Failure Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Chronic Heart Failure in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Chronic Heart Failure Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Chronic Heart Failure Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Chronic Heart Failure market.

Chronic Heart Failure Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Chronic Heart Failure Report Insights

- Patient Population in Chronic Heart Failure
- Therapeutic Approaches in Chronic Heart Failure
- Chronic Heart Failure Pipeline Analysis
- Chronic Heart Failure Market Size and Trends
- Chronic Heart Failure Market Opportunities
- Impact of upcoming Therapies in Chronic Heart Failure

Chronic Heart Failure Report Key Strengths

- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition

Chronic Heart Failure Report Assessment

- Current Treatment Practices in Chronic Heart Failure
- Unmet Needs in Chronic Heart Failure
- Market Attractiveness
- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Chronic Heart Failure market
- Organize sales and marketing efforts by identifying the best opportunities for Chronic Heart Failure market
- To understand the future market competition in the Chronic Heart Failure market.

Additional Details

Publisher : Delve Insight

Reference : DIMI0055
Number of Pages : 100
Report Format : PDF
Publisher Information :



DELVEINSIGHT
INSIGHTS. EXPERTISE. ACTIONABLE DATA.

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Table Of Contents for Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027

[Report Updated: 14-02-2018]

- 1. Report Introduction
- 2. Chronic Heart Failure Market Overview at a Glance
 - 2.1. Market Share Distribution of Chronic Heart Failure in 2017
 - 2.2. Market Share Distribution of Chronic Heart Failure in 2027
- 3. Disease Background and Overview: Chronic Heart Failure
 - 3.1. Introduction
 - 3.2. Symptoms
 - 3.3. Etiology
 - 3.4. Risk Factors
 - 3.5. Pathophysiology
 - 3.6. Diagnosis
 - 3.7. Treatment
- 4. Epidemiology and Patient Population
 - 4.1. Key Findings
 - 4.2. Total Prevalent/ Incident Patient Population of Chronic Heart Failure in 7MM
 - 4.3. Total Prevalent Patient Population of Chronic Heart Failure in 7MM - By Countries
- 5. Epidemiology of Chronic Heart Failure by Countries
 - 5.1. United States
 - 5.1.1. Assumptions and Rationale
 - 5.1.2. Prevalent/Incident Cases of the Chronic Heart Failure
 - 5.1.3. Sub-Type Specific cases of the Chronic Heart Failure
 - 5.1.4. Sex- Specific Cases of the Chronic Heart Failure
 - 5.1.5. Diagnosed Cases of the Chronic Heart Failure
 - 5.1.6. Treatable Cases of the Chronic Heart Failure
 - 5.2. EU
 - 5.3. Assumptions and Rationale
 - 5.4. Germany
 - 5.4.1. Assumptions and Rationale
 - 5.4.2. Prevalent/Incident Cases of the Chronic Heart Failure
 - 5.4.3. Sub-Type Specific cases of the Chronic Heart Failure
 - 5.4.4. Sex- Specific Cases of the Chronic Heart Failure
 - 5.4.5. Diagnosed Cases of the Chronic Heart Failure
 - 5.4.6. Treatable Cases of the Chronic Heart Failure
 - 5.5. France
 - 5.5.1. Assumptions and Rationale
 - 5.5.2. Prevalent/Incident Cases of the Chronic Heart Failure
 - 5.5.3. Sub-Type Specific cases of the Chronic Heart Failure
 - 5.5.4. Sex- Specific Cases of the Chronic Heart Failure
 - 5.5.5. Diagnosed Cases of the Chronic Heart Failure
 - 5.5.6. Treatable Cases of the Chronic Heart Failure
 - 5.6. Italy
 - 5.6.1. Assumptions and Rationale
 - 5.6.2. Prevalent/Incident Cases of the Chronic Heart Failure
 - 5.6.3. Sub-Type Specific cases of the Chronic Heart Failure
 - 5.6.4. Sex- Specific Cases of the Chronic Heart Failure
 - 5.6.5. Diagnosed Cases of the Chronic Heart Failure
 - 5.6.6. Treatable Cases of the Chronic Heart Failure
 - 5.7. Spain
 - 5.7.1. Assumptions and Rationale
 - 5.7.2. Prevalent/Incident Cases of the Chronic Heart Failure
 - 5.7.3. Sub-Type Specific cases of the Chronic Heart Failure
 - 5.7.4. Sex- Specific Cases of the Chronic Heart Failure
 - 5.7.5. Diagnosed Cases of the Chronic Heart Failure
 - 5.7.6. Treatable Cases of the Chronic Heart Failure
 - 5.8. United Kingdom
 - 5.8.1. Assumptions and Rationale
 - 5.8.2. Prevalent/Incident Cases of the Chronic Heart Failure
 - 5.8.3. Sub-Type Specific cases of the Chronic Heart Failure
 - 5.8.4. Sex- Specific Cases of the Chronic Heart Failure
 - 5.8.5. Diagnosed Cases of the Chronic Heart Failure
 - 5.8.6. Treatable Cases of the Chronic Heart Failure
 - 5.9. Japan
 - 5.9.1. Assumptions and Rationale
 - 5.9.2. Prevalent/Incident Cases of the Chronic Heart Failure
 - 5.9.3. Sub-Type Specific cases of the Chronic Heart Failure
 - 5.9.4. Sex- Specific Cases of the Chronic Heart Failure
 - 5.9.5. Diagnosed Cases of the Chronic Heart Failure
 - 5.9.6. Treatable Cases of the Chronic Heart Failure
 - 6. Current Treatment & Medical practices
 - 6.1. Treatment Algorithm
 - 6.2. Treatment Guidelines
 - 7. Unmet Needs of the Chronic Heart Failure
 - 8. Marketed Therapies
 - 8.1. Drug A: Company 18
 - 8.1.1. Drug Description
 - 8.1.2. Mechanism of Action
 - 8.1.3. Regulatory Milestones
 - 8.1.4. Advantages & Disadvantages
 - 8.1.5. Product Profile
 - 8.2. Drug B: Company 28
 - 8.2.1. Drug Description
 - 8.2.2. Mechanism of Action
 - 8.2.3. Regulatory Milestones
 - 8.2.4. Advantages & Disadvantages
 - 8.2.5. Product Profile
 - 9. Pipeline Therapies – At a glance
 - 10. Key Cross Competition
 - 11. Emerging Therapies for Chronic Heart Failure
 - 11.1. Drug C: Company 31
 - 11.1.1. Drug Description
 - 11.1.2. Clinical Trials Details
 - 11.1.3. Safety and Efficacy Profile
 - 11.1.4. Advantages & Disadvantages
 - 11.1.5. Pipeline Development Activities
 - 11.1.6. Product Profile
 - 11.2. Drug D: Company 41
 - 11.2.1. Drug Description
 - 11.2.2. Clinical Trials Details
 - 11.2.3. Safety and Efficacy Profile
 - 11.2.4. Advantages & Disadvantages
 - 11.2.5. Pipeline Development Activities
 - 11.2.6. Product Profile
 - 12. Chronic Heart Failure : 7MM Market Analysis
 - 12.1. 7MM Market Size of Chronic Heart Failure
 - 12.2. 7MM Percentage Share of drugs marketed for Chronic Heart Failure
 - 12.3. 7MM Market Sales of Chronic Heart Failure by Products
 - 13. Chronic Heart Failure : Country-Wise Market Analysis
 - 13.1. United States
 - 13.1.1. Market Size of Chronic Heart Failure in United States
 - 13.1.2. Percentage Share of drugs marketed for Chronic Heart Failure in United States
 - 13.1.3. Market Sales of Chronic Heart Failure by Products in United States
 - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
 - 13.2. EU-5
 - 13.2.1. Germany
 - 13.2.1.1. Market Size of Chronic Heart Failure in Germany
 - 13.2.1.2. Percentage Share of drugs marketed for Chronic Heart Failure in Germany
 - 13.2.1.3. Market Sales of Chronic Heart Failure by Products in Germany
 - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
 - 13.2.2. France
 - 13.2.2.1. Market Size of Chronic Heart Failure in France
 - 13.2.2.2. Percentage Share of drugs marketed for Chronic Heart Failure in France
 - 13.2.2.3. Market Sales of Chronic Heart Failure by Products in France
 - 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
 - 13.2.3. Italy
 - 13.2.3.1. Market

Size of Chronic Heart Failure in Italy13.2.3.2. Percentage Share of drugs marketed for Chronic Heart Failure in Italy13.2.3.3. Market Sales of Chronic Heart Failure by Products in Italy13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market13.2.4. Spain13.2.4.1. Market Size of Chronic Heart Failure in Spain13.2.4.2. Percentage Share of drugs marketed for Chronic Heart Failure in Spain13.2.4.3. Market Sales of Chronic Heart Failure by Products in Spain13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market13.2.5. United Kingdom13.2.5.1. Market Size of Chronic Heart Failure in United Kingdom13.2.5.2. Percentage Share of drugs marketed for Chronic Heart Failure in United Kingdom13.2.5.3. Market Sales of Chronic Heart Failure by Products in United Kingdom13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market13.3. Japan13.3.1. Market Size of Chronic Heart Failure in Japan13.3.2. Percentage Share of drugs marketed for Chronic Heart Failure in Japan13.3.3. Market Sales of Chronic Heart Failure by Products in Japan13.3.4. Analysis of Upcoming Therapies and their Impact on the Market14. Market Drivers15. Market Barriers16. Appendix17. Report Methodology17.1. Sources18. DelveInsight Capabilities19. Disclaimer20. About DelveInsight*Indication Specific

List Of Tables in Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Chronic Heart Failure in 7MM

Table 2: Total Prevalent/Incident Cases of the Chronic Heart Failure in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Chronic Heart Failure in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Chronic Heart Failure in United States (2016-2027)

Table 5: Sex- Specific Cases of the Chronic Heart Failure in United States (2016-2027)

Table 6: Diagnosed Cases of the Chronic Heart Failure in United States (2016-2027)

Table 7: Treatable Cases of the Chronic Heart Failure in United States (2016-2027)

Table 8: Prevalent/Incident Cases of the Chronic Heart Failure in Germany (2016-2027)

Table 9: Sub-Type Specific cases of the Chronic Heart Failure in Germany (2016-2027)

Table 10: Sex- Specific Cases of the Chronic Heart Failure in Germany (2016-2027)

Table 11: Diagnosed Cases of the Chronic Heart Failure in Germany (2016-2027)

Table 12: Treatable Cases of the Chronic Heart Failure in Germany (2016-2027)

Table 13: Prevalent/Incident Cases of the Chronic Heart Failure in France (2016-2027)

Table 14: Sub-Type Specific cases of the Chronic Heart Failure in France (2016-2027)

Table 15: Sex- Specific Cases of the Chronic Heart Failure in France (2016-2027)

Table 16: Diagnosed Cases of the Chronic Heart Failure in France (2016-2027)

Table 17: Treatable Cases of the Chronic Heart Failure in France (2016-2027)

Table 18: Prevalent/Incident Cases of the Chronic Heart Failure in Italy (2016-2027)

Table 19: Sub-Type Specific cases of the Chronic Heart Failure in Italy (2016-2027)

Table 20: Sex- Specific Cases of the Chronic Heart Failure in Italy (2016-2027)

Table 21: Diagnosed Cases of the Chronic Heart Failure in Italy (2016-2027)

Table 22: Treatable Cases of the Chronic Heart Failure in Italy (2016-2027)

Table 23: Prevalent/Incident Cases of the Chronic Heart Failure in Spain (2016-2027)

Table 24: Sub-Type Specific cases of the Chronic Heart Failure in Spain (2016-2027)

Table 25: Sex- Specific Cases of the Chronic Heart Failure in Spain (2016-2027)

Table 26: Diagnosed Cases of the Chronic Heart Failure in Spain (2016-2027)

Table 27: Treatable Cases of the Chronic Heart Failure in Spain (2016-2027)

Table 28: Prevalent/Incident Cases of the Chronic Heart Failure in UK (2016-2027)

Table 29: Sub-Type Specific cases of the Chronic Heart Failure in UK (2016-2027)

Table 30: Sex- Specific Cases of the Chronic Heart Failure in UK (2016-2027)

Table 31: Diagnosed Cases of the Chronic Heart Failure in UK (2016-2027)

Table 32: Treatable Cases of the Chronic Heart Failure in UK (2016-2027)

Table 33: Prevalent/Incident Cases of the Chronic Heart Failure in Japan (2016-2027)

Table 34: Sub-Type Specific cases of the Chronic Heart Failure in Japan (2016-2027)

Table 35: Sex- Specific Cases of the Chronic Heart Failure in Japan (2016-2027)

Table 36: Diagnosed Cases of the Chronic Heart Failure in Japan (2016-2027)

Table 37: Treatable Cases of the Chronic Heart Failure in Japan (2016-2027)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 42:7MM- Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 43:7MM- Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 44: United States-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 45: United States-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 46: United States-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 47: Germany-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 48: Germany-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 49: Germany-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 50: France-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 51: France-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 52: France-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 53: Italy-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 54: Italy-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 55: Italy-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 56: Spain-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 57: Spain-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 58: Spain-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 59:UK-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 60:UK-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 61:UK-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 62: Japan-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Table 63: Japan-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Table 64: Japan-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

List Of Figures, Charts and Diagrams in Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Figure 1: Total Prevalent/Incident Cases of the Chronic Heart Failure in 7MM

Figure 2: Total Prevalent/Incident Cases of the Chronic Heart Failure in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Chronic Heart Failure in United States (2016-2027)

Figure 4: Sub-Type Specific cases of the Chronic Heart Failure in United States (2016-2027)

Figure 5: Sex- Specific Cases of the Chronic Heart Failure in United States (2016-2027)

Figure 6: Diagnosed Cases of the Chronic Heart Failure in United States (2016-2027)

Figure 7: Treatable Cases of the Chronic Heart Failure in United States (2016-2027)

Figure 8: Prevalent/Incident Cases of the Chronic Heart Failure in Germany (2016-2027)

Figure 9: Sub-Type Specific cases of the Chronic Heart Failure in Germany (2016-2027)

Figure 10: Sex- Specific Cases of the Chronic Heart Failure in Germany (2016-2027)

Figure 11: Diagnosed Cases of the Chronic Heart Failure in Germany (2016-2027)

Figure 12: Treatable Cases of the Chronic Heart Failure in Germany (2016-2027)

Figure 13: Prevalent/Incident Cases of the Chronic Heart Failure in France (2016-2027)

Figure 14: Sub-Type Specific cases of the Chronic Heart Failure in France (2016-2027)

Figure 15: Sex- Specific Cases of the Chronic Heart Failure in France (2016-2027)

Figure 16: Diagnosed Cases of the Chronic Heart Failure in France (2016-2027)

Figure 17: Treatable Cases of the Chronic Heart Failure in France (2016-2027)

Figure 18: Prevalent/Incident Cases of the Chronic Heart Failure in Italy (2016-2027)

Figure 19: Sub-Type Specific cases of the Chronic Heart Failure in Italy (2016-2027)

Figure 20: Sex- Specific Cases of the Chronic Heart Failure in Italy (2016-2027)

Figure 21: Diagnosed Cases of the Chronic Heart Failure in Italy (2016-2027)

Figure 22: Treatable Cases of the Chronic Heart Failure in Italy (2016-2027)

Figure 23: Prevalent/Incident Cases of the Chronic Heart Failure in Spain (2016-2027)

Figure 24: Sub-Type Specific cases of the Chronic Heart Failure in Spain (2016-2027)

Figure 25: Sex- Specific Cases of the Chronic Heart Failure in Spain (2016-2027)

Figure 26: Diagnosed Cases of the Chronic Heart Failure in Spain (2016-2027)

Figure 27: Treatable Cases of the Chronic Heart Failure in Spain (2016-2027)

Figure 28: Prevalent/Incident Cases of the Chronic Heart Failure in UK (2016-2027)

Figure 29: Sub-Type Specific cases of the Chronic Heart Failure in UK (2016-2027)

Figure 30: Sex- Specific Cases of the Chronic Heart Failure in UK (2016-2027)

Figure 31: Diagnosed Cases of the Chronic Heart Failure in UK (2016-2027)

Figure 32: Treatable Cases of the Chronic Heart Failure in UK (2016-2027)

Figure 33: Prevalent/Incident Cases of the Chronic Heart Failure in Japan (2016-2027)

Figure 34: Sub-Type Specific cases of the Chronic Heart Failure in Japan (2016-2027)

Figure 35: Sex- Specific Cases of the Chronic Heart Failure in Japan (2016-2027)

Figure 36: Diagnosed Cases of the Chronic Heart Failure in Japan (2016-2027)

Figure 37: Treatable Cases of the Chronic Heart Failure in Japan (2016-2027)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41: 7MM- Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 42: 7MM- Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 43: 7MM- Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 44: United States-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 45: United States-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 46: United States-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 47: Germany-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 48: Germany-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 49: Germany-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 50: France-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 51: France-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 52: France-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 53: Italy-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 54: Italy-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 55: Italy-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 56: Spain-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 57: Spain-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 58: Spain-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 59:UK-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 60:UK-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 61:UK-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 62: Japan-Market Size of Chronic Heart Failure in USD MM (2016-2027)

Figure 63: Japan-Market Share Chronic Heart Failure by Therapies in USD MM (2016-2027)

Figure 64: Japan-Market Sales of Chronic Heart Failure by Therapies in USD MM (2016-2027)

How to Buy...

Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/201754>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$6250** | Single User Price
- \$12500** | Site License Price
- \$18750** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.